Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

1953 - Progastrin, a new blood biomarker for the diagnostic and therapeutic monitoring, in gastro-intestinal cancers: A BIG-RENAPE project.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Benoit You

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

B. You1, V. Kepenekian2, A. Prieur3, M. Caceres4, L.F. Payen-Gay5, P. Liaud3, M. Flaceliere3, M. Tod6, L. Villeneuve7, F. Bibeau8, L. Bernard7, P. Jourdan-Enfer7, N. Medeghri9, D. Dayde9, S. Calattini9, G. Freyer1, D. Maucort-Boulch4, D. Joubert10, O. Glehen2

Author affiliations

  • 1 Medical Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 2 Surgical oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 3 Ecs-screening, ECS-Screening, 1004 - Lausanne/CH
  • 4 Biostatistics, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 5 Biology, Hospices Civiles de Lyon, 69002 - Lyon/FR
  • 6 Emr Ucbl/hcl 3738, Univesité Claude Bernard Lyon 1, 10 - Oullins/FR
  • 7 8. department Of Public Health, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 8 Service D'anatomie Pathologique, CHU de Caen, 14033 - Caen/FR
  • 9 Plateforme Transversale Ic-hcl, Institut de Cancérologie des Hospices Civils de Lyon, PIERRE BENITE/FR
  • 10 Canton De Vaud, ECS-Screening, 1004 - Lausanne/CH
More

Resources

Abstract 1953

Background

Progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, uterus, melanoma…), as the progastrin gene is a direct target of the WNT/ß-catenin oncogenic pathway involved in tumorigenesis of many organs (ASCO 2017, Prieur et al CCR 2017). The value of progastrin as a diagnostic, and as a therapeutic monitoring marker, was assessed in patients treated for peritoneal carcinomatosis from gastro-intestinal (GI) cancers in the prospective BIG-RENAPE study (NCT02823860).

Methods

Patients were enrolled during management of peritoneal carcinomatosis (before or after neo-adjuvant chemotherapy, or surgery) and then regularly sampled for blood. Progastrin was measured using the ELISA DECODE LAB test®. The diagnostic value of progastrin concentrations at inclusion in 190 GI cancer patients (test set) was assessed against 80 samples from French donors (control set with non-cancer subjects). The longitudinal therapeutic monitoring value of progastrin test was also investigated.

Results

The Area Under the ROC curve of prograstrin for cancer diagnosis was 0.87, 95% CI [0.83-092]. Progastrin was significantly elevated at inclusion in all GI tumor subtypes (p < 0.0001; median 3.08, 95% CI [1.15-7.23], including colo-rectal & small bowel (n = 151; median 2.78) and oeso-gastric (n = 33; median 4.75) carcinomas). During monitoring, progastrin levels decreased after neoadjuvant treatment (median value 2.20, n = 23), decrease that became significant after surgery (p < 0.0001, median value 1.57, n = 84), with patients going back to normal value and others not. A trend for better PFS was observed in patients with progastrin decline after surgery. Progastrin baseline value did not correlate with renal function.

Conclusions

Progastrin assay is a simple and inexpensive blood test exhibiting high diagnostic accuracy in patients with GI carcinomas, along with promising therapeutic longitudinal changes across sequential managements. Assessment of progastrin value as a multi-tumor screening assay, and as a monitoring test, is on-going.

Clinical trial identification

Legal entity responsible for the study

BIG-RENAPE.

Funding

ECS-Screening.

Editorial Acknowledgement

Disclosure

A. Prieur, P. Liaud, M. Flaceliere, D. Joubert: Employee: ECS-Screening. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings